Background The prevalence of celiac disease (CD) has rapidly increased over recent decades, but costs related to CD remain poorly quantified. Objective This systematic review assessed the economic burden of CD in North America and Europe. Methods MEDLINE, EMBASE, EconLit, and the Cochrane Library databases were systematically searched to identify English-language literature from 2007 to 2018 that assessed costs, cost effectiveness, and health resource utilization for CD. Results Forty-nine studies met the inclusion criteria, of which 28 (57.1%) addressed costs of testing and diagnosis; 33 (67.3%) were from Europe. The cost per positive CD diagnosis of testing patients already undergoing esophagogastroduodenoscopy for other indications ranged from 1300 Canadian dollars ($Can) in Canada (2016 value) to €44,712 in the Netherlands (2013 value). Adding the CD test was cost effective when it combined diagnostic modalities (e.g., serology and biopsy). Direct annual excess costs to a US payer per diagnosed CD patient totaled $US6000 (2013 value) more than for a person without CD, chiefly due to outpatient care. Hospitalizations, emergency visits, and medication use were more common with CD. After initiating a gluten-free diet (GFD), patients visited primary care providers less often, used more medications, and missed fewer days from school and work. Conclusions Most of the few available economic studies of CD assess testing and diagnosis costs, especially in Europe. Methods of testing generally are considered cost effective when they combine diagnostic modalities in symptomatic patients. Most costs to a payer of managing CD derive from outpatient care. Following GFD initiation, patients lose fewer days from work and school than pretreatment.
Introduction
Celiac disease (CD) is a human leukocyte antigen (HLA)-associated chronic autoimmune disorder of the small intestine driven by adaptive immune responses to gluten peptides in wheat, barley, and rye [1] . The prevalence of CD in the general population is estimated to be 1% in North America and Western Europe [2, 3] . The rapidly rising prevalence of diagnosed CD among American adults, estimated to be as much as fivefold over the last 30 years [4] , has been attributed to increases in serological testing and potential changes in environmental exposures that increase risk for disease development [4, 5] . However, diagnosis can be challenging because CD may present with a variety of signs and symptoms, some non-specific. Symptoms of classic CD include diarrhea and malabsorption [6] , but patients may also suffer from extra-intestinal symptoms, such as iron-deficiency anemia, fatigue, and headache [7] . In children, recurrent abdominal pain [3] and growth problems, such as failure to thrive and short stature, can also occur [3, 6] .
Although improved awareness and the introduction of active case finding have increased detection [4, [8] [9] [10] , CD remains widely underdiagnosed [3, 10, 11] . Case-finding programs have been recommended [3, 10] , but the costs and use of resources are important considerations in determining the need for testing and choice of methods [12] [13] [14] . Costeffectiveness analyses (CEAs) help to provide guidance on whether the benefit of identifying more individuals with CD justifies the costs, and which factors affect the cost effectiveness of case-finding programs. Notably, individuals with CD who remain undiagnosed may incur substantial costs to healthcare systems if they require care for the symptoms and complications of uncontrolled disease.
The cost of diagnostic testing affects both patients and the healthcare system, including time spent by healthcare workers to conduct diagnostic procedures and to process and analyze patient results. The gold standard for diagnosis uses a combination of methods, which begins with minimally invasive serological testing for CD autoantibodies that include immunoglobulin A (IgA), immunoglobulin G (IgG), and/or tissue transglutaminase (TTG) IgA. TTG IgA is the standard antibody measured in CD [15] . Diagnosis is then confirmed by duodenal biopsy with histological analysis [15] . Other methodologies, such as HLA genotyping, are utilized when diagnosis is uncertain or biopsy is not available. If a diagnosis of CD is made according to these criteria, then the patient is advised to seek professional dietary counseling to begin a gluten-free (GF) diet (GFD) for disease management.
At present, the only treatment option for patients with CD is strict adherence to a GFD [10] . However, adherence to a GFD carries its own costs to patients and healthcare systems, including consultations with a dietician and purchases of GF foods [10, [16] [17] [18] [19] [20] . While a GFD can normalize the symptoms and serologic and histologic abnormalities associated with CD, many patients often experience recurrent symptoms [3, 21, 22] . In addition, the potential complications and co-morbidities of CD may require monitoring and treatment, even in patients with strict GFD adherence [3, 10, 16] . The diet, symptoms, complications, and co-morbidities of CD necessitate the use of medical services, including doctor and emergency room visits and hospitalizations [16, 23] . Patients also experience school or work absenteeism [17, 18, 24] . The resulting excess healthcare utilization and indirect costs are likely to incur a significant societal burden for both patients with CD and their insurers. To assess the direct and indirect costs associated with CD in North America and Europe, a systematic review was performed to identify studies regarding costs, CEAs, and health resource utilization (HRU) for CD.
Methods
A systematic literature review using MEDLINE (PubMed), EMBASE, EconLit, and the Cochrane Library databases was performed to identify published studies spanning February 2007 through June 2017, and updated through to June 2018, to assess the economic burden of CD. Search strategies identified literature published in English during the last 11 years including abstracts, but case reports and narrative reviews were excluded. Our search strategy for MEDLINE (via PubMed) is provided in Electronic Supplementary Material Appendix 1. This search was adapted and utilized across all four electronic databases. Manual backwards citation tracking of references from identified studies and review articles was performed to identify additional relevant studies. Searches were also performed in abstracts presented at the following conferences from 2015 to 2017: Digestive Disease Week, American College of Gastroenterology (ACG), and United European Gastroenterology Week.
Two reviewers (ESM and KJC) independently screened the search results to select a list of titles to be considered as sources for the review. Two reviewers (ESM and KJC) screened all potential full-text citations independently, with discrepancies resolved by a third reviewer (TB). To be included in the literature review, studies (primary studies, systematic reviews, meta-analyses, or economic models) had to be conducted in patients with CD from North America or Europe and had to report direct or indirect medical costs, costs of diagnosing and/or screening for CD, or HRU. Publications were excluded if they were published prior to 11 years before the search or were conference abstracts presented prior to 2015.
Two reviewers (ESM and KJC) abstracted all data using a standardized tool, with disagreements resolved by discussion or a third reviewer (TB). Screening and data abstraction was performed using DistillerSR (Evidence Partners, Ottawa, ON, Canada).
Results

Study Characteristics
The literature search yielded 984 citations (Fig. 1) . After removal of duplicates and title/abstract screening, 91 articles were eligible for full-text review. After screening, 49 were included in the systematic literature review.
Thirteen studies reported HRU used by patients with CD [16] [17] [18] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] ; 11 reported on direct costs [16, 23, 25, 28-32, 59, 60, 62] ; seven examined the costs of GF food products [19, 20, 23, [33] [34] [35] [36] ; four reported on absenteeism or performance [17, 18, 24, 37] ; and 11 reported on a combination of topics [16-18, 23-25, 28-32] . Twenty-one reported on costs of testing and diagnosis [14, 24, 29, 30, [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] , and six CEAs [12, 13, [55] [56] [57] [58] assessed strategies for diagnosing and screening CD. Most of the articles (n = 33) were from Europe [13, 17-20, 23-27, 29-32, 34-43, 45, 46, 48, 49, 51-53, 59, 60] , followed by the USA (n = 12) [14, 16, 28, 33, 47, 50, 55-58, 61, 62] , Canada (n = 2) [44, 54] other (n = 2) [12, 45] . There were 27 retrospective studies (20 of which were database analyses) [14, 16, 18, 23-31, 35-37, 45-51, 53, 54, 60-62] , 16 prospective studies (eight of which were surveys) [17-20, 32-34, 38-44, 59, 63, 64] , and six cost-effectiveness models [12, 13, [55] [56] [57] [58] .
Testing and Diagnosis Costs
Guidelines for the use of autoantibody testing in the diagnosis of CD in adults and children provide recommendations based on algorithms generated by the results of CD autoantibody titers [65, 66] . Gonzalez et al. [39] examined the most cost-effective diagnostic strategy with the utilization of algorithms in laboratory testing and quantifying IgA and/ or TTG IgA titers in all patients. This prospective study performed in Spain compared one group of 1678 patients with autoantibody testing referrals deemed appropriate by review to another group of 2140 patients in which the test referrals were not reviewed or restricted [39] . There were advantages of opportunistic screening to detect CD-associated autoantibodies over restricting laboratory testing. The utilization of a suitable algorithm was more cost effective than opting for the cheapest test kit; for example, the lowest cost per case diagnosed (€4.63 per patient; 2017 value) was found in the algorithm using only TTG IgA testing [39] . The authors proposed that CD diagnostic efficiency and cost reduction could be improved by foregoing efforts to exclude inappropriate testing and the use of testing algorithm beginning with TTG IgA determination [39] . A retrospective chart review in the USA confirmed the use of a standardized algorithm (including the proposal of TTG IgA if negative, followed by IgA testing) for CD laboratory testing would provide significant cost savings without compromising screening sensitivity [61] . Several economic studies have assessed the cost effectiveness of serological testing. A study of 250 healthy Italian children reported that screening with serum TTG cost €5000 annually, rising to €11,250 if anti-endomysial (EMA) testing was additionally performed on every child (year of not values not reported) [45] . Elevated titers of EMA indicate CD, but the test is not as sensitive as TTG testing as 5-10% of celiac patients have negative test results [63] . Since EMA testing has a high concordance rate with TTG testing and TTG is the recommended gold standard for screening and is less expensive, EMA testing was not deemed worth the additional cost. An Irish study also calculated the cost savings of eliminating the EMA test to determine if TTG alone was sufficient prior to biopsy for the diagnosis of CD. Regardless of the EMA testing result, there was no significant difference observed in CD diagnosis when patients presented with high clinical suspicion. This suggests that CD diagnostic testing using TTG alone is sufficient where clinical suspicion is high [53] . In the Netherlands, measuring TTG cost €15.10 per sample and complete blood work had a mean (standard deviation [SD]) cost of €124 (€58) (2017 values) [32] . It was estimated that this strategy, in which a positive TTG result would lead directly to biopsy, could save €6038 per patient diagnosed (2012-2013 values) over 2 years [53] . Adding an anti-deaminated gliadin peptide (DGP) test to complement TTG was similarly judged as not being cost effective. In a study of Swedish children, the DGP test identified too few positive diagnoses to warrant the extra costs (€49,940 per case; 2008-2010 value) [51] .
Population screening and case finding of CD in both adults and pediatric populations to detect undiagnosed CD in relatives of CD patients are not widely utilized by general practitioners. General population screening has been deemed both cost prohibitive and ineffective as asymptomatic patients have low compliance to a GFD and testing yields many false results [67] . Case finding to diagnose CD in symptomatic patients presenting conditions known to be associated with CD has been a more supported strategy but is also costly. However, the development of validated, rapid methods of IgA [68, 69] , TTG [70] [71] [72] , and DGP [73, 74] antibody detection at the point-of-care tests (POCT) using blood from finger pricks in the primary care setting has recently allowed for a comparative cost analysis between the two diagnostic strategies and against standard serological testing.
The use of POCT in CD case finding and screening was more cost effective than using the standard serological approach. Two studies examined the incorporation of POCT in European primary care settings to identify new cases of CD in adults [38, 42] . One study examined the effectiveness of IgA/DGP-IgG-based POCT (Symtomax ® , Augurix, Monthey, Switzerland) [38] and one study evaluated TTG IgA [42] . It has been recently demonstrated that Symtomax ® has equivalency to standard serology for biopsy-proven CD, is more reliable than TTG-based POCT, and patients prefer POCT over venepuncture [74, 75] .
Additionally, POCT screening may be more cost effective than simple case finding to diagnose CD in symptomatic adult patients. In a primary care setting, Scoglio et al. [42] compared the diagnostic yield of POCT-based screening for new cases of CD versus case finding in the same population using conventional serology and biopsy histology as the gold standard. In this prospective study, Sicilian adults < 75 years of age (n = 2197) were screened by POCT for TTG IgA (Biocard™ Celiac Test, AniBiotech, Vantaa, Finland) and were systematically searched for symptoms or conditions associated with higher risk for CD. The cost of each POCT was €2.5 (2017 value) [42] . Thirty-six (1.6%) and 671 (30.5%) of patients were POCT positive and symptomatic at case finding, respectively. Every patient then received routine CD diagnostic work-up, including serology and endoscopic biopsy (if serology positive), to confirm the sensitivity (75%; 95% confidence interval [CI] 30.1-95.4) and specificity (99.2%; 95% CI 97.5-99.7) of POCT results [42] . Six (0.27%) new celiac patients were identified by POCT screening and case finding [42] . The total cost for POCT screening was €7497.35 (mean cost per patient €1499.47; 2017 values) compared with the case-finding cost of €9855.14 (mean cost per patient €1971.03; 2017 values) [42] . POCT screening had a 24% lower cost than case finding. Additionally, when case finding was followed with POCT screening in symptomatic patients, the total cost was €2345.84 (mean cost per patient €588.46; 2017 values) [42] . The utilization of POCT screening may support diagnosis improvement in the primary care setting for symptomatic patients and lessen costs when compared with the simple case-finding strategy.
HLA genotyping has been proposed to be the most efficient and cost effective first-line screening tool in children presenting with symptoms associated with CD. To assess the risk of CD in children presenting with juvenile idiopathic arthritis (JIA) (n = 95), Skrabl-Baumgartner et al. [43] performed an age-and sex-matched (n = 110 controls) prospective cohort study of Caucasian children in Austria to compare the cost effectiveness of gold-standard diagnostic methods to that of HLA genotyping. CD was diagnosed in four (4.2%) patients, which was significantly greater than in controls (P < 0.02) and 14 times greater than in the general population [43] . HLA genotyping identified 26 (27.4%) patients with one of the variants of the risk genotypes and all four new cases of CD had a HLA-DQ2.5 variant genotype, with 22 patients requiring repeated serological screening based on their HLA genotypes [43] . CD-specific antibodies were not observed in patients without HLA-DQ2/DQ8 genotypes. The authors concluded the determination of HLA-DQ2/DQ8 genotyping eliminated the need for repeated serological testing in patients with JIA. By using HLA genotyping as first-line screening tool and foregoing repeated serological testing, this cohort could save €1855.34 in the first 2 years, and as much as €2012.73 every year thereafter to monitor costs (2017 values) [43] . These cost-saving estimates for patient monitoring are based on a HLA genotyping cost of €44.03 (2017 value) [43] .
HLA genotyping may be a cost-effective screening strategy for some populations, but it might not be able to be successfully broadly applied to save costs. Screening first-and second-degree relatives of CD patients with HLA typing prior to TTG testing did not identify more cases or justify the cost of adding the test to the screening strategy. A decision analysis performed using a US third-party payer perspective calculated that for the HLA typing strategy to become cost effective when used before serological testing, it would need to be at least 22% less expensive (a cost decrease of $US301 to $US234; 2005 values) [14] .
Deciding which patients to test for CD is controversial; guidelines do not offer consensus regarding which signs, symptoms, laboratory abnormalities, and/or associated comorbidities require CD evaluation [10] . For patients with symptoms or conditions closely associated with CD and undergoing endoscopy to provide a definitive diagnosis, the cost of adding routine duodenal biopsy to increase detection of CD can be substantial in some settings, and may yield only a handful of additional CD diagnoses [46] [47] [48] [49] [50] 54] . Across studies that assessed the results of a duodenal biopsy during routine endoscopy, pathology was rarely associated with a diagnosis of CD; 1-3% of biopsies were consistent with CD. According to a Canadian study, only 3% of biopsies showed abnormal histology for CD and the cost per positive CD finding totaled 3024 Canadian dollars ($Can) (year not reported) [54] . A UK study estimated the cost per positive case of CD was £18,839 (2018 values) in 719 TTG negative or non-serology-assessed patients, whereby only 0.27% of biopsies confirmed diagnosis [40] . A study from the Netherlands estimated the cost at €30,000 (year not reported), with more than 577 patients needing to be biopsied to diagnose one CD patient [46] . Costs per positive CD diagnosis, including biopsy for CD and upper endoscopy for other indications, are detailed in Table 1 .
Eliminating biopsy in patients with positive TTG may save costs in pediatric populations. In symptomatic children with positive serology, the 2012 European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) guidelines allow a CD diagnosis to be made without small bowel biopsy in select cases [66] . Two prospective studies, one in the UK [41] and one in Canada [44] , validated recommended serological diagnosis guidelines. Paul et al. [41] suggested that these criteria can be extended to high-risk asymptomatic children who undergo serologic testing for reasons such as family history of CD, Down syndrome, or diabetes mellitus. Of 157 asymptomatic highrisk children diagnosed with CD from March 2007 through February 2017, 84 had positive serology (TTG titers > 10 times the upper normal limit), and biopsy confirmed the CD diagnosis in all. Employing the ESPGHAN guidelines for these asymptomatic, high-risk cases would save an estimated £1275 (2018 value) per child [41] . Similarly, Wu et al. [44] noted a cost savings of $Can1155 (2018 value) per patient not requiring endoscopy.
Economic Modeling
Six CEAs were identified by this literature review [12, 13, [55] [56] [57] [58] . Most (83.3%) used a US third-party payer perspective, and all assessed the cost effectiveness of different strategies for diagnosing CD. Nearly all included time horizons spanning the lifetime of a patient. Table 2 lists the patient populations and screening techniques used by these models.
TTG serology prior to esophagogastroduodenoscopy (EGD)/biopsy was estimated to offer the most cost-effective [56] . All screening strategies were compared with TTG serology testing alone, with TTG serology prior to EGD/biopsy being the most cost effective. It was not judged to be worth the additional high cost to screen TTG-negative patients for IgA deficiency prior to EGD/biopsy. In all cases of suspected CD, EGD/biopsy alone without first screening for positive serology was the costliest strategy per each additional positive diagnosis.
Among specific patient populations (e.g., those with irritable bowel syndrome [IBS], gastroesophageal reflux disease [GERD], or iron-deficiency anemia), universal screening for CD appeared cost effective with various strategies compared with no screening. A US CEA from a Medicare perspective (2014 US dollars) comparing routine duodenal biopsy during EGD versus no biopsy in patients with refractory GERD estimated that, compared with no biopsy, the biopsy strategy cost $US55,693 per CD case detected and $US121,875 per quality-adjusted life-year (QALY) gained [58] . The strategy became cost effective (using the traditional $US50,000/QALY) when the prevalence of CD among patients with refractory GERD exceeded 1.8% [58] . Another model assessed the cost effectiveness of targeted screening of patients with diarrhea-type or mixed-type IBS versus no screening in IBS patients in the Netherlands (2009 euros) and concluded that EGD/biopsy in patients with positive serology was cost effective compared with no screening [13] . In a population with iron-deficiency anemia, once the cost of biopsy fell below $US67 (2014 value) (cost of biopsy range $US60-80 [2013 values]), routine duodenal biopsy during EGD dominated (was both less expensive and more effective than) testing of serology first prior to biopsy [55] .
Universal screening is not cost effective in all patient populations. While undiagnosed and untreated CD can increase the risk of complications, including bone loss and fracture, universal serologic screening during early adolescence to maintain bone health was not estimated to be cost effective. The standard practice of screening only high-risk (patients with type 1 diabetes, Down syndrome, Turner syndrome, IgA deficiency, systemic lupus erythematosus, autoimmune thyroiditis, or those who have a first-and/or second-degree relative with CD) or symptomatic patients should be continued, and not expanded; this was the dominant economic screening technique identified in the USA [57] .
Many models estimated that the cost effectiveness of screening strategies was highly sensitive to the prevalence of CD in the modeled population. ACG guidelines for the diagnosis and management of CD recommend routine biopsy during EGD in patient populations where the probability of CD is at least 5% [10] . Strategies may still be cost effective in populations with a lower prevalence of CD, as the approaches evaluated by most models in this review remained cost effective if the prevalence of CD exceeded 1% [12, 55, 58] .
Health Resource Utilization
The utilization of healthcare resources by celiac patients has been measured by 13 studies (Table 3) . Three compared utilization by CD patients with that of matched healthy controls in the USA [16] , UK [23] , and Italy [26] , and six additional retrospective database studies quantified HRU in the USA [28] , UK [29, 30] , Sweden [27, 31] , and Spain [25] among people with CD. Four other studies in Europe used a pre-post design to evaluate changes in HRU with diagnosis and/or initiation of a GFD [17, 18, 24, 32] . In Scandinavia, but not in the UK, utilization in most categories drops following diagnosis and treatment.
People with CD use more healthcare resources than their counterparts without CD. Six comparisons in European children (Italy, Sweden, UK), Swedish women, all ages in the UK, and working-age US adults have reported greater rates of HRU in categories that include hospitalizations, medications, and outpatient care and follow-up visits [18, 26, 27, [29] [30] [31] . In two European studies, greater resource use by celiac patients than controls without CD was noted even 4-5 years after diagnosis and treatment [26, 27] . Among 1294 Italian children and young adults with CD, the risk of hospitalization for any cause was twice that of matched controls (hazard ratio 2.34; 95% CI 2.08-2.63) [26] . Children with CD also had significantly more prescriptions in most drug categories than children without CD, peaking in the first year following diagnosis [26] . A retrospective database study in the UK analyzed outpatient appointments made by CD patients (n = 1317) between 2005 and 2016 [29] . Over 11 years, 33,150 outpatient appointments were made, with 9.8% for gastroenterology, including pediatric gastroenterology, services. The remaining appointments were for dietetic (4.4%), ophthalmology (4.3%), dermatology (2.8%), audiology (2.7%), and others (76%) related to CD complications. The number of appointments per patient ranged from one to 167, with an average of 25.17 appointments over the course of 11 years (2.29 appointments per person per year) [29] . Notably, the monitoring of patients for complications associated with CD increased resource use [30] . A Swedish study reported that the total mean (SD) number of outpatient visits per pediatric patient per year ranged from 0.7 (0.6) to 1.0 (0.5), with more pediatrician visits than dietician visits [31] .
It has been proposed that the follow-up of patients with CD could shift from the standard medical provider to online consultations and dietician-led outpatient visits for cost Consultations, outpatient referrals, and prescriptions CD was associated with significant primary care costs. Post-diagnosis, annual per-patient costs increased a significant 91% in CD patients (primary care). Costs increased during the immediate post-diagnosis timeframe and were also higher during the time immediately before diagnosis. While costs stabilized at about 6 years after diagnosis, they continued to be higher than before diagnosis savings and GFD compliance. A multicenter, randomized clinical trial of CD children and young adults (≤ 25 years) in the Netherlands compared the control group (traditional care at an outpatient clinic with their own physician) to an online group (patients or parents completed questionnaire using the web for follow-up). In comparison to traditional outpatient consultations, online consultations via e-healthcare web-based platforms were cost saving by €202 (medical savings of €138; non-medical savings of €64; 2018 values) and increased CD-specific quality of life for children and young adults when observed at the 6-month follow-up [32] . Moreover, the use of online consultations detected health problems more frequently than traditional visits (P < 0.001), while the growth problems and lack of dietary adherence were similar between types of consultations (P = 0.059) [32] . Forty-eight percent of the patients in the online group regarded the consultation to be "as good as outpatient care" and 58% planned to continue the online consultations to manage their care [32] . HRU is still higher in CD patients who are in remission than in matched controls. In a study of Swedish women, 137 CD patients who were in remission for a median of 4 years continued to use more healthcare resources than 411 matched controls, primarily in the number of mental and behavioral health visits. The authors speculate that women with CD experience more co-morbidities despite effective use of a GFD, noting that "it is probably not enough to follow a GFD to feel well" [27] . Regardless of remission status, 12,187 CD patients identified in a US database had higher rates of hospitalizations and emergency department (ED), outpatient, and dietician visits than matched controls without CD. HRU by the 83.5% of patients in full remission was lower and closer to that of controls than HRU by the 16.5% of patients in partial remission over the 1-year study period [16] . Nonetheless, all-cause HRU between CD patients in full remission versus matched controls as well as CD patients in partial remission versus matched controls was statistically significant for all comparisons (P < 0.0001) [16] .
In addition to remission status, certain subgroups of CD patients may be more likely to be hospitalized, visit an ED, or have longer hospital stays than others. These may include young adults and women. HRU by people with CD in the USA was quantified by Skef et al. [28] in a conference abstract based on ED and hospitalization databases. The mean length of hospital stay decreased by 1.3 days between 2006 (6.8 days) and 2011 (5.5 days) [28] . Patients aged 18-44 years old were more likely to visit the ED (vs. patients aged 45-84 years), as were women compared with men (69.7 vs. 30.3%). As age progressed, hospital admission rates were higher [28] .
When CD is diagnosed and patients start a GFD, they tend to use fewer healthcare resources in Scandinavia, but this is not the case in the UK. Four studies in the UK and Scandinavia using a pre-post design compared HRU before and after patients begin GFD treatment. Hospitalizations were measured several different ways: a study of Finnish children found fewer hospitalizations post-diagnosis and treatment and a study of Swedish adults found fewer hospitalization days [18, 24] . Among Finnish adults, however, there was no change in the percentage of people hospitalized after beginning a GFD [17] . Finnish adults and children used fewer medications and less primary care post-diagnosis and treatment, and Swedish adults similarly had fewer healthcare visits. However, Finnish children visited specialists more often after starting a GFD than Finnish or Swedish adults [17, 18, 24] . In contrast, UK patients of all ages with CD used more healthcare resources, including primary care visits and prescriptions, after diagnosis, which likely reflects unique aspects of the National Health Service (NHS). Unlike in Finland or Sweden, GF foods can be prescribed by physicians in the UK and are covered by the NHS. This sharply increases HRU following diagnosis, with a study of nearly 12,000 UK residents with CD identified in the General Practice Research Database finding that they averaged 14.3 prescriptions (including those for food) annually during the decade before diagnosis, rising to 40.7 annually afterward [23] . Patients also logged more annual primary care visits (5.8 vs. 6.9) and tests (1.9 vs. 3) after diagnosis, but these rates fell substantially in the years following diagnosis. The authors attribute this post-diagnosis burst of HRU to screening for celiac co-morbidities [23] .
Other Direct and Indirect Costs
Other Direct Costs Associated with Celiac Disease (CD)
Direct costs incurred by CD patients were reported by 11 studies. Three assessed direct costs of CD patients using databases in the USA [16, 28, 62] , reflecting the availability of claims databases in that country, while six additional database studies estimated costs in the UK [23, 29, 30, 60] , Spain [25] , or Sweden [31] . Two prospective studies examined direct costs: one in the Netherlands [32] and another in a multinational study that projected the economic burden of CD in the Mediterranean area in the year 2020 [59] .
Costs incurred by patients with CD place a significant burden on third-party payers (e.g., health insurance companies, managed care, preferred provider networks, government agencies) across the USA [16, 62] . Total all-cause direct costs for CD patients in the USA can be more than twice those of healthy controls, mainly due to the excessive medical costs associated with outpatient care [16] . In a large database study of 12,187 patients with CD from the OptumHealth Reporting and Insights database (1998-2013), it was reported that all-cause total annual direct costs of CD were $US7282 higher than in matched controls ($US12,217 vs. $US4935; P < 0.0001; 2013 values). The total all-cause medical costs, which included hospitalizations, ED and outpatient visits, visits to other practitioners such as gastroenterologists and nutritionists, and prescription drug costs, were $US5991 higher annually for CD patients than controls without a medical claim for CD (based on International Classification of Diseases 9th Revision [ICD-9] 579.0) matched by sex, age, geographic region, index date, and employment status [16] . Mean total all-cause costs were $US6076 higher for full-remission patients and $US13,410 higher for patients with partial remission than for non-CD matched controls, suggesting substantial costs for patients with uncontrolled disease [16] . In another analysis of a US population-based cohort of CD patients identified by ICD-9 579.0 (n = 153), substantial incremental attributable costs (~ $US4000) were incurred by patients with CD compared with non-CD matched control subjects over the 4 years prior to diagnosis (estimated cumulative costs: $US11,037 vs. $US7073; 2007 values) [62] .
Outpatient visits and hospitalizations for CD patients account for a large percentage of the excess cost of CD when compared with matched controls without CD. An analysis of medical claims from January 1998 through March 2013 calculated that outpatient-related costs represented 69% of the excess all-cause medical costs incurred by third-party payers in the USA, while hospitalization accounted for 28% [16] . A retrospective database review of 1317 CD patients (all ages) in the UK over 11 years indicated the cost to the local trust of diagnosis, treatment, and follow-up of CD patients was a total of £5,167,396 (2017 value) [29] . The total cost of outpatient appointments with specialties other than gastroenterology was £4,704,538 (2017 value), which were attributed to dietitian, dermatology, and other services to manage CD [29] . Based on 2.29 appointments per year per patient, the estimated cost range for new and follow-up outpatients were £481-607 and £190-311, respectively (2017 values) [29] . Similarly in Sweden, the total mean (SD) cost for all outpatient visits (pediatrician and dietician) per pediatric patient per year ranged from 362 (335) to 625 (431) Swedish krona from 2011 to 2016 [31] . Incomplete or unclear guideline recommendations for monitoring of CD complications and disease management by follow-up of patients add to these costs annually [30] . From 2006 to 2011, the mean hospitalization cost per stay for a CD patient in the USA increased from $US24,149 to $US30,137 (P < 0.05), with patients aged 45-84 years representing the largest burden, and with an annual aggregate cost to all payers (from the Nationwide Inpatient Sample) of $US11,854,250 (P < 0.001) [28] . Costs related to ED visits had a lesser impact, but still represented 3% of excess costs [16] .
While costs are higher for CD patients than for people without CD, earlier detection of the disease, and therefore earlier initiation of a GFD, might help reduce costs for a US third-party payer because costs tend to fall after diagnosis. An analysis of a US population-based cohort of CD patients and matched controls reported that in the year following a CD diagnosis, total direct costs dropped by $US2118 on average (2007 values) [62] . Both inpatient and outpatient costs also fell, by $US1338 and $US742, respectively [62] . A retrospective claims analysis of US patients enrolled with CIGNA HealthCare reported mean direct annual medical costs decreased from $US8502 to $US7854 per person 36 months after CD diagnosis due to decreased utilization of inpatient and ED visits (2003 values) [76] .
In the UK, GF food can be prescribed to diagnosed patients by their general practitioner and costs for the GFD may be covered by the healthcare system; as a result, healthcare costs do not fall after diagnosis. In one database study, annual costs for CD patients in the UK were £91 higher than that of controls before diagnosis, and £354 higher afterward (2009-2010 values) [23] . These differences are mainly attributed to increased costs for prescriptions after diagnosis, which include GF foods and dietary supplements [23] . However, one study estimated the number of GF prescriptions in the UK has dropped by 0.5 million between 2013 and 2017, with a corresponding cost reduction of £6.7 million (2017 value) [60] . This drop was attributed to changing policies in the UK and variation in prescribing between different practices and geographic location, mostly determined by the preferences of clinicians and local health services [60] .
Current data for direct costs associated with CD in other parts of the world were not available. However, the prevalence of CD is growing worldwide, and the subsequent economic burden is projected to continue to rise. In Mediterranean countries, including Albania, Bosnia, Croatia, Malta, Morocco, Slovenia, and parts of Western Europe, medical costs for symptomatic CD patients prior to diagnosis are projected to reach approximately €4 billion by 2020, with children accounting for €387 million (2007 values) [59] .
Cost of Gluten-Free Foods
Once diagnosed, the current treatment for a CD patient is strict adherence to a GFD, which can be costly to the patient in many countries. Six studies (in Austria, Greece, the USA, and the UK) examined the cost and availability of GF foods, and all found that GF foods are significantly more expensive than their gluten-containing equivalents [19, 20, [33] [34] [35] [36] . Additionally, the nutritional composition is compromised in GF foods [35] . When compared with conventional food products, supermarket and pharmacy GF staple products (e.g., breads, pastas, crackers, pretzels, and cookies) were 240% (in US dollars; P < 0.05) to 518% (in UK pounds sterling; P < 0.001) more expensive than regular products [19, 20, 23, [33] [34] [35] [36] . Depending on age and purchase place, Panagiotou and Kontogianni [36] estimated the weekly economic burden of a GFD in Greece ranged from €12 to €28 per person (2017 values) [36] . The nutritional composition of GF foods trended towards having less fiber and protein and more fat, sugar, and salt than regular foods, demonstrating that the nutritional composition was inferior in the more expensive prescribed GF foods than commercial equivalents (P < 0.05) [35] .
GF staple foods can currently be prescribed and may be reimbursed in the UK with qualification, similar to medications, under the British National Formulary (BNF). In one analysis, the average annual cost to the NHS of prescriptions for BNF Category 9 (Food and Nutrition) for patients with CD increased 25-fold after diagnosis (£10 vs. £246 per patient; 2010 values) [23] . Specifically, a more detailed analysis within this BNF category showed that GF and special diet food supplements contributed to 89% of the increased annual prescription costs after diagnosis (£1.80 before vs. £220 after diagnosis per patient; 2010 values) [23] . The mean prescription cost per item was £14.41 (2017 value) in 2017 [60] . The authors of this study noted that while this increases prescription costs following diagnosis of a CD patient in the UK, the same costs occur in the USA but are simply borne by the patient instead of the insurer [23] .
In any country, availability of GF products may be an important contributor to their high costs. Health-food stores and supermarkets in the studies on this topic were more likely to carry GF items than budget stores and corner shops, but these sources were also more expensive [20, 33, 34] . Online retailers had the greatest availability of GF food, but also the highest costs [20, 33] .
Absenteeism and Performance Due to CD
Three studies on absenteeism due to CD, all postal questionnaires from Finland and Sweden, and one study regarding the cognitive performance of CD children in Sweden were identified. Two Finnish studies surveyed members (both children and adults) of the Finnish Celiac Society [17, 18] , while the third study (Swedish) surveyed members of the Swedish Society for CD patients to assess absenteeism from school or work before and after a CD diagnosis [24] . Diagnosis of CD and subsequent initiation of a GFD yielded varied results in the self-reported number of missed school and work days for children and adults in Scandinavia [17, 18, 24] . In Swedish patients (n = 1031), treatment with a GFD significantly reduced the number of days missed from school or work. In the year prior to diagnosis, patients missed 7.2 days compared with 2.5 during the year afterward (P < 0.001) [24] . Similarly, a questionnaire among 132 Finnish children with CD found that with treatment they missed fewer days from daycare or school (6.7 days pre-vs. 5 days post-treatment; P = 0.277) and their parents missed fewer days from work (4.5 days pre-vs. 1.5 days post-diagnosis; P = 0.073); however, the results were not statistically significant [18] . In a survey of adult CD patients in Finland (n = 700), fewer sick days were reported than in an unmatched general population cohort for both the year prior to their diagnosis and the year after diagnosis [17] . A study examining CD children (n = 1767) from Sweden found no association between CD and school performance at the ninth-grade level [37] .
Discussion
To date, this is the first systematic review of the economic literature in CD. As the incidence and prevalence of this disease rise in Western countries, attention has turned in recent years toward its costs-49 economic studies were identified that met the set inclusion criteria. Most economic literature pertaining to a chronic disease of industrialized countries typically report on direct treatment costs in the USA, where there are large claims-based databases to use for retrospective analyses. The economic literature in CD differs from this pattern in that most (33 of 49) studies are European [13, 17-20, 23-27, 29-32, 34-43, 45, 46, 48, 49, 51-53, 59, 60] , and only a minority (n = 11) exclusively focus on direct costs [16, 23, 25, 28-32, 59, 60, 62] . Seven studies reported costs for GF foods [19, 20, [33] [34] [35] [36] , four of which were from the UK where GFD costs were reimbursed by the healthcare system and therefore would be considered direct costs of CD care [20, 23, 34, 35] . Most (29 of 44) [12-14, 38-58, 61, 64] report or model costs associated with screening and diagnosis, with a relatively large number of CEAs (6 of 29) [12, 13, [55] [56] [57] [58] . Indirect costs usually form a small subset of the economic literature; similarly, the current review identified four reports on absenteeism from work or school [17, 18, 24] or school performance [36] .
Diagnosis of CD by serological examination and smallbowel biopsy with histological analysis is the gold standard of care. Sole use of serological testing does not necessarily provide a confirmatory diagnosis, as biopsy and histological analysis of the duodenum are also needed for a firm diagnosis in most (adult) patients. The primary serological test detects TTG IgA in individuals over the age of 2 years [10] . Total IgA measurement may also be considered if a high probability of CD exists [10, 56] . An alternative approach is to test for both TTG and DGP antibodies. Anti-gliadin (AGA) and EMA antibodies are also routinely measured in CD diagnosis. After serological testing, CD diagnosis is confirmed by small-bowel biopsy via upper endoscopy with histopathological characteristics of partial to complete villous atrophy, crypt hyperplasia, and lymphocytic infiltration of the epithelium and lamina propria [6, 10] . HLA typing is not typically used in the routine initial diagnosis of CD, but can be used to rule out CD, strengthen pediatric diagnoses, confirm a diagnosis in patients with negative CD-specific antibodies or inconclusive biopsy results, and avoid initiation of a GFD in high-risk groups.
Identifying CD appears to be most cost effective when TTG testing is followed by EGD/biopsy to confirm the diagnosis, which supports recommendations from US and European guidelines. With inexpensive and reliable serological tests, duodenal biopsy is not recommended for the exclusion of CD [40] . When compared with no screening, strategies using either EGD/biopsy or serology alone were not considered cost effective in patients screened for CD. Cost per positive CD diagnosis of screening patients already undergoing upper gastrointestinal endoscopy for other indications, such as anemia or IBS, were highly variable and ranged from approximately $Can1300 in Canada [54] to more than €44,000 in the Netherlands (costing year not reported) [46] . It should be noted that models did not consider the costs of missing a true diagnosis, which would likely influence their calculations.
It is clear that a diagnosed CD patient costs payers more than a matched control without CD, chiefly due to outpatient care, which comprises about two-thirds of costs [16] . In the USA, direct annual excess costs to a US payer per diagnosed CD patient totaled $US4000 (2007 value) to $US6000 (2013 value) more than for a person without CD [16, 62] . These estimates suggest that the excess cost of managing CD is more than the excess cost of managing other common chronic diseases, such as asthma ($US3259; 2009 value) [77] or rheumatoid arthritis ($US2085; 2008 value) [78] , but less than others such as diabetes ($US7900; 2012 value) [79] . CD patients continue to use more healthcare than controls even 4-5 years after diagnosis and initiation of a GFD [26, 27] . These are chiefly outpatient services, although hospitalization and emergency visits are also more common than in controls without CD, and CD patients use more medications [16, 26, 27] . Mental and behavioral health are particularly important categories of outpatient care among CD patients, even those with controlled disease, suggesting areas of need unmet by the GFD [27] .
Undiagnosed CD patients cost payers more than those diagnosed patients. Unless they are asymptomatic, or they successfully implement and follow a GFD without medical advice, undiagnosed patients are likely to incur costs related to CD symptoms and complications even if the costs are not attributed to CD. These costs drop following diagnosis and adherence to the GFD [62] . In pre-versus post-diagnosis comparisons, patients visit primary care providers less often after diagnosis [17, 18, 24] and miss fewer days from school and work (in two of three studies) [17, 18, 24] . In CD children, utilization of dieticians rather than pediatricians for routine CD follow-up resulted in similar levels of dietary compliance and reduced costs [31] . Thus, diagnosing CD patients and using dietician-led outpatient clinics may reduce costs, after incurring costs related to the diagnosis itself and screening for any complications that may have developed. Therefore, payers should be motivated to diagnose and treat patients as early as possible in the disease process, not only for the cost benefit but because evidence suggests that diagnostic delays are associated with the development of refractory disease, which would generate even higher costs [16, 80] . Cost effectiveness was shown to support POCT utilization in the primary care setting [38, 42] , with more cost savings when applied to screening rather than case finding [42] .
The exception to costs falling after diagnosis occurs in the UK [23] , where GF foods have formerly been prescribed and reimbursed. In other countries, these costs are simply transferred to patients, who pay 240-518% more for GF foods than for gluten-containing equivalents in the USA and UK, respectively [19, 23, [33] [34] [35] [36] . However, following public consultation [81], the NHS-England has restricted the prescription and reimbursement of GF foods to save costs [82] . National Prescribing Guidelines provide recommendations (by age and sex) on the amount of GF staple food prescription eligibility per month [82] . Unlike other countries in the UK that provide free prescriptions, England now requires a qualification for GF food prescription reimbursement. To lower out-of-pocket cost for patients, the new prescription charge per GF food item in England has been reduced to £8.80 (2018 value) and quarterly or annual prepayment certificates for unlimited prescriptions are being applied [82] . With this change, there will be an opportunity to study the effects on adherence among CD patients to a GFD without reimbursement, and whether this results in clinical consequences for the patients. It would also be instructive to assess whether subsequent higher costs to the payer for these clinical consequences would negate savings garnered by ending reimbursement for GF products.
In addition to price and availability of GF foods, other factors contribute to increased costs, including the consumption of naturally GF products and supplements. The consumption of fresh fruit and vegetables and healthy sources of protein are recommended to maintain a healthy diet; however, these products are also associated with high cost due to their perishability [83] . Moreover, a GFD can be nutritionally deficient due to low fiber [35] and vitamin content [84] . For these reasons, and because of varying degrees of ongoing malabsorption, supplements are commonly prescribed to CD patients and contribute to the economic burden.
Future work on the economics of CD should explore the issue of demographic groups at risk of incurring high costs related to CD. These risks occur at different stages in the CD diagnosis and treatment process. Among people who have not been diagnosed, elderly people are especially likely to remain undiagnosed, and may incur higher costs. Clinicians do not expect to encounter CD in this population, and these patients are also more likely to present with extra-intestinal symptoms rather than classic gastrointestinal complaints, further hindering diagnosis [85, 86] . After diagnosis, adolescents represent the age group with the greatest difficulty adhering to the GFD [81, 87] , which results in clinical effects that raise costs. Young adults and women are the groups more likely to visit the ED [28] .
The economic studies examined by this review addressed CD-related costs globally rather than those related to the many complications attributed to this disease, from infertility to cancer. Because CD itself is common, chronic, and treated only with a GFD, studies of costs related to the disease thus tend to focus on screening, diagnosis, and visits to outpatient clinicians. This is likely why more studies have been performed in Europe than is typical for an economic body of literature, without the need for a US healthcare claims database to assess direct costs of treatment. Complete analyses of the economics of CD will not include the full cost of this condition until the incidence of these complications and the associated costs to treat them are considered. Adding these downstream costs to economic models may suggest that some upstream expenses associated with earlier and more aggressive screening may be more cost effective than is currently suggested.
Conclusions
Most economic studies of CD have focused on the cost of testing and diagnosis, especially in Europe. Methods of testing are generally considered cost effective when they combine diagnostic modalities, such as TTG serology then biopsy, in symptomatic or high-risk individuals. Universal biopsy of patients undergoing endoscopy for symptoms or conditions closely associated with CD may not be recommended due to the high cost per diagnosis. A diagnosed CD patient costs payers more than a matched control without CD primarily due to increased outpatient costs. However, a diagnosed CD patient costs payers less than an undiagnosed CD patient because costs generally fall after diagnosis. Much of the cost to a payer of managing CD derives from outpatient care, especially for patients with poorly controlled disease. Patients on a GFD often lose fewer days from work and school but pay high costs for GF foods.
To fill data gaps and inform cost-effective treatment strategies, future research should investigate demographic groups at risk for incurring high costs and should include the costs of treatment for CD complications.
